hrcak mascot   Srce   HID

Pregledni rad
https://doi.org/10.21860/medflum2017_182951

Pathohistological diagnosis of prostate cancer

Gordana Đorđević ; Zavod za opću patologiju i patološku anatomiju, Medicinski fakultet, Sveučilište u Rijeci, Rijeka, Hrvatska
Sanja Štifter ; Zavod za opću patologiju i patološku anatomiju, Medicinski fakultet, Sveučilište u Rijeci, Rijeka, Hrvatska
Christophe Štemberger ; Zavod za opću patologiju i patološku anatomiju, Medicinski fakultet, Sveučilište u Rijeci, Rijeka, Hrvatska

Puni tekst: hrvatski, pdf (2 MB) str. 252-263 preuzimanja: 2.616* citiraj
APA 6th Edition
Đorđević, G., Štifter, S. i Štemberger, C. (2017). Patohistološka dijagnostka karcinoma prostate. Medicina Fluminensis, 53 (3), 252-263. https://doi.org/10.21860/medflum2017_182951
MLA 8th Edition
Đorđević, Gordana, et al. "Patohistološka dijagnostka karcinoma prostate." Medicina Fluminensis, vol. 53, br. 3, 2017, str. 252-263. https://doi.org/10.21860/medflum2017_182951. Citirano 12.07.2020.
Chicago 17th Edition
Đorđević, Gordana, Sanja Štifter i Christophe Štemberger. "Patohistološka dijagnostka karcinoma prostate." Medicina Fluminensis 53, br. 3 (2017): 252-263. https://doi.org/10.21860/medflum2017_182951
Harvard
Đorđević, G., Štifter, S., i Štemberger, C. (2017). 'Patohistološka dijagnostka karcinoma prostate', Medicina Fluminensis, 53(3), str. 252-263. https://doi.org/10.21860/medflum2017_182951
Vancouver
Đorđević G, Štifter S, Štemberger C. Patohistološka dijagnostka karcinoma prostate. Medicina Fluminensis [Internet]. 2017 [pristupljeno 12.07.2020.];53(3):252-263. https://doi.org/10.21860/medflum2017_182951
IEEE
G. Đorđević, S. Štifter i C. Štemberger, "Patohistološka dijagnostka karcinoma prostate", Medicina Fluminensis, vol.53, br. 3, str. 252-263, 2017. [Online]. https://doi.org/10.21860/medflum2017_182951

Sažetak
Prostate cancer (PCa) is the most common male cancer in Europe and the US. The early diagnosis relies on prostate specifc antigen serum test, digito-rectal and ultrasound examinaton. Definitve verificaton is pathohistological with individual assesment of aggressiveness of the tumor potental through prognostc parameters such as Gleason gradus/grade groups, percentage and number of affected cilinders in the biopsy, stage and positve margins in prostatectomy. These parameters signifcantly affect the choice and protocol of therapies but can not identfy a localized, clinically signifcant cancer that will certainly cause metastatc disease and require treatment. Therefore, researchers focused on molecular biomarkers that are important in prognosis, pathogenesis, and as a target molecules for possible therapy. The article contributes to a better understanding of the pathohistological findings and new facts about the molecular pathogenesis of tumors, which are important for the care of patients with prostate cancer.

Ključne riječi
molecular biomarkers; prognostic factors; prostate cancer

Hrčak ID: 184827

URI
https://hrcak.srce.hr/184827

[hrvatski]

Posjeta: 2.795 *